Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N
First Department of Surgery, University of Tokushima School of Medicine, Japan.
Clin Cancer Res. 1998 Jun;4(6):1475-82.
It is difficult to determine the prognosis of patients with hepatocellular carcinoma (HCC). Assessment of the clinicopathological and biological malignancy of HCC may help in determining treatment strategies and predicting outcome. The tumor DNA content, p53 protein expression, proliferating cell nuclear antigen labeling index, and argyrophilic proteins of nuclear organizer regions were used as markers of biological malignancy. A correlation between these biological parameters and clinicopathological factors was sought. DNA aneuploidy was observed in 31 of 80 tumors (38.8%). Aneuploidy increased as differentiation decreased. The overall survival rate of patients with aneuploid tumors was significantly poorer than that of patients with diploid tumors. p53 overexpression was observed in 18 of 80 tumors (22.5%). The incidence of p53 positivity increased significantly with increasing tumor size and poorer differentiation. The overall survival rate of p53-positive patients was significantly worse than that of p53-negative patients. The proliferating cell nuclear antigen labeling index and the mean number of argyrophilic proteins of nuclear organizer regions were higher in more poorly differentiated lesions. We conclude that DNA ploidy and p53 expression are useful prognostic indicators in HCC. Cell proliferation increases as HCC progresses. With progression, tumors tend to become more poorly differentiated.
肝细胞癌（HCC）患者的预后难以确定。评估HCC的临床病理和生物学恶性程度可能有助于确定治疗策略并预测预后。肿瘤DNA含量、p53蛋白表达、增殖细胞核抗原标记指数和核仁组成区嗜银蛋白被用作生物学恶性程度的标志物。研究了这些生物学参数与临床病理因素之间的相关性。80个肿瘤中有31个（38.8%）观察到DNA非整倍体。随着分化程度降低，非整倍体增加。非整倍体肿瘤患者的总生存率明显低于二倍体肿瘤患者。80个肿瘤中有18个（22.5%）观察到p53过表达。p53阳性的发生率随着肿瘤大小增加和分化程度降低而显著增加。p53阳性患者的总生存率明显低于p53阴性患者。在分化较差的病变中，增殖细胞核抗原标记指数和核仁组成区嗜银蛋白的平均数较高。我们得出结论，DNA倍体和p53表达是HCC有用的预后指标。随着HCC进展，细胞增殖增加。随着进展，肿瘤往往分化更差。
